Cardigant Medical Inc. is a development-stage biotechnology company. The Company focuses on the use of biologics and combination biologics and devices for the treatment of acute coronary syndromes (ACS) and aortic valve stenosis (AVS). The Company focuses on local drug delivery for the treatment of cardiovascular and peripheral vascular disease. Its primary focus is on treating atherosclerosis and plaque stabilization in both the coronary and peripheral vasculature, as well as stenosis of the aortic valve using systemic delivery of large molecule therapeutics based on high density lipoprotein (HDL) targets. The Company�s also focuses on the use of targeted local delivery to reduce systemic exposure and drug dosage. The Company uses a synthetically modified protein based on the Apolipoprotein A-I (Apoa-1) structure, which is found in HDL.